Heramed Ltd · ASX:HMD
Heramed — Investor Presentation (April 2022)
23 slides from Heramed's investor presentation, Apr 26, 2022
Slide 1: Leading the Digital Transformation of Maternity Care
For personal use only LEADING THE DIGITAL TRANSFORMATION OF MATERNITY CARE Investor Presentation HeraMED Limited (ASX:HMD) April 2022 All Rights Reserved Page 1 © 2022 HeraMED Ltd.
Slide 2: Disclaimer
Disclaimer For personal use only Important notice regarding forward looking statements This document contains a general summary of the Company and is provided for information purposes only. For full details please review HeraMED Limited ASX page - https://www.asx.com.au/asx/share-price-research/comp
Slide 3: Ongoing Pregnancy Challenges
Ongoing Pregnancy Challenges For personal use only Doctors/ Providers Expectant Mothers Shortage of fundamental services 14+ clinical sessions per pregnancy (Low-risk) Lack of time and attention Loss of time away from work / home Low reliability of analysis Personal anxiety and stress Episodic, Reac
Slide 4: Cost of maternity complications
Cost of maternity complications* Opportunity to reduce costs and improve maternity care and outcomes For personal use only US$111bn US Maternal Healthcare Market PP Depression Preeclampsia C-section Preterm Birth US$14bn US$2.2bn US$9bn US$26bn *Numbers represent US healthcare cost only, global cost
Slide 5: HeraCARE: A New Era of Connected Maternity Care
HeraCARE A New Era of Connected Maternity Care – Watch the video -> Aggregates and manages medical data of multiple sources, optimizing workflows and Health Care allowing healthcare providers to be better informed and effective patient advocates. Provider For personal use only HeraBEAT FHR Blood Pre
Slide 6: HeraCARE's Core Value Proposition
HeraCARE’s Core Value Proposition For personal use only Delivers value in three key categories Increased Satisfaction Better Outcomes Cost Reduction Reassurance and peace of mind Early detection of complications Reduction of clinic visits Exceptional convenience Stress and depression reduction Optim
Slide 7: HeraBEAT Smart Fetal HR Home Monitor
HeraBEAT Smart Fetal HR Home Monitor– Watch the video -> For personal use only FHR / MHR Smart Detection Detects fetal and maternal heart rate. Guided Search Easy to follow, step-by-step guidance 142 BPM Reliable & Shareable Data Medical-grade data accuracy >400,000 Fetal Heart Rate Measurements AND
Slide 8: HeraBEAT a hospital grade standard
HeraBEAT a hospital grade standard Peer reviewed Independent clinical trial at JHC shows outstanding results For personal use only Comparison between the HeraBEAT and the industry gold standard Medical Grade Accuracy Validated ± 1 bpm Results Featured in Globally Recognized Scientific Journal 100% 96
Slide 9: HeraBEAT Low And High Risk Fetal Monitoring
HeraBEAT Low And High Risk Fetal Monitoring For personal use only Low risk High risk Fetal HR Auscultation (1-5min) NST - Non Stress Test (20-30 min) *Full NST available worldwide, not yet available in the US All Rights Reserved Page 9 © 2022 HeraMED Ltd.
Slide 10: Adoption By Medical Leaders Around The World
Adoption By Medical Leaders Around The World For personal use only Multiple pilot discussions with Healthcare providers Collaboration agreement, Paid pilot Collaboration agreement, clinical trial and equity investment Clinical Trial in process Commercial Agreement All Rights Reserved Page 10 © 2022
Slide 11: Australia Success Story
Australia Success Story Dr. Paul Porter M.D. For personal use only “The HeraBEAT device is accurate and + easy to use by clinicians in the hospital and expectant mothers at home. The fetal heart rate data obtained at home is HeraCARE was implemented as the new equivalent to that obtained in the stan
Slide 12: HeraCARE @JHC increased adoption rate
HeraCARE @JHC increased adoption rate For personal use only +500 users Increasing adoption rate + Over 500 HeraCARE users so far increasing at a pace of ~70 week Dr Cliff Neppe - Head of OB at JHC: ~6000 +2000 HeraBEAT FHR Over the past 18 months, we have shown that a novel, Data Points Measurements
Slide 13: USA Success Story
USA Success Story Dr Pandipati - Clinical Lead for virtual OB For personal use only Program: + “We have seen incredible patient AND provider satisfaction ratings through the pilot, including extra high marks from providers in the patient HeraCARE was implemented to power Virtual OB safety category,
Slide 14: HeraCARE Cost Effectiveness
HeraCARE Cost Effectiveness For personal use only Optimising hospital and medical staff time HeraCARE > 10-15 min VS Traditional > 45-60 Min HeraCARE > 6-8 visits VS Traditional > 14 Visits (Low risk) HeraCARE Total > 448 Min VS Traditional > 840 Min Reduction of up to 47% in staff time HeraCARE cos
Slide 15: Diverse Commercial Models
Diverse Commercial Models Channel partner / customer categories For personal use only Hospitals and One-off hardware clinics device sale ~US$150-200 Maternity health groups Monthly SaaS fee ~US$39-59 Digital health per pregnant platforms woman per month B2B2C offering to leading groups Health with p
Slide 16: HeraMED Value Proposition
HeraMED Value Proposition End-to-end solution drives value for multiple stakeholders For personal use only Expectant Mothers Clinical Staff Hospitals Empowerment Improved outcomes Operational Efficiencies Convenience Patient satisfaction Customer Loyalty Peace of Mind Reduced burden Innovation Ident
Slide 17: Near-Term Company Catalysts
Near-Term Company Catalysts For personal use only ● Technological and Clinical Superiority HeraCARE and HeraBEAT redefining home-based maternity care, already proven technological and clinical superiority and have collaboration agreements with leading medical organisations. ● Commercial Pilots and Cl
Slide 18: The HeraMED Opportunity
The HeraMED Opportunity Well placed to deliver on significant opportunity in maternal telehealth globally For personal use only Proprietary platform Developed by medical The only medical grade, Patent pending using hardware and engineers and clinical clinically validated, protected hardware, softwar
Slide 19: HeraMED Limited
For personal use only HeraMED Limited (ASX:HMD) David Groberman CEO and Co-founder E: David@hera-med.com M: +972-52-6991188 Pac Partners Tim Chapman E: tchapman@pacpartners.com.au M: +61 4-1989-7062 Investor Relations The Capital Network Julia Maguire E: julia@thecapitalnetwork.com.au M: +61 2-8999-
Slide 20: Company Milestones
Company Milestones For personal use only Q4 2018 Q4 2019 Q4 2019 Q2 2020 Q3 2020 Q3 2020 IPO Mayo Clinic FDA 510K Freeman road agreement for clinical Mayo Clinic Investment & Clinical trial @JHC Collaboration Agreement Clearance trials and pilots in Australia Funding Initiated Q4 2020 Outstanding Cl
Slide 21: Ukrainian humanitarian support in collaboration with Sheba
Ukrainian humanitarian support in collaboration with Sheba For personal use only HeraMED donated devices and professional support for the use of HeraBEAT and HeraCARE in the field Hospital by Sheba in Ukraine HeraMED Appears in TV coverage on Israeli Tech assisting the Ukrainian cause All Rights Res
Slide 22: Corporate Overview
Corporate Overview ASX code HMD For personal use only Listing date December 2018 GICS classification Health Care Equipment & Services Share price (24 April 2022) $0.15 Market Capitalisation (24 April 2022) $36.46m Shares on issue 188.2m Cash on hand (31 December 2021) $3.559m Trading range (last 12 m
Slide 23: Board & Management
Board & Management Dr. Ron Weinberger Highly-experienced international business executive with strong scientific background For personal use only Non-Executive Former Director, President and CEO of Nanosonics Ltd. (ASX: NAN), Mkt cap ~$2 billion Chairman CEO and MD of EMVision Ltd. ASX:EMV, Non-Exec